Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Stargardt Disease 1 Clinical Trial

Official title:
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease

Status Active, not recruiting

Clinical Trial Summary

To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03364153
Study type	Interventional
Source	Astellas Pharma Inc
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	January 12, 2018
Completion date	April 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04281732` - Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision
Recruiting	`NCT05258032` - Structural and Functional Characterization of Rare Ocular Diseases
Active, not recruiting	`NCT06300476` - Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)	Phase 1/Phase 2
Recruiting	`NCT05674058` - Function and Imaging Assessments for G1961E-associated Stargardt Disease
Completed	`NCT03297515` - Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease	N/A
Active, not recruiting	`NCT05244304` - Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1	Phase 3
Not yet recruiting	`NCT06388083` - A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease	Phase 2/Phase 3
Enrolling by invitation	`NCT03772938` - Stem Cells Therapy in Degenerative Diseases of the Retina	Phase 1